These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34342720)

  • 1. Targeting the mu-Opioid Receptor for Cancer Treatment.
    Zhang H; Zhou D; Gu J; Qu M; Guo K; Chen W; Miao C
    Curr Oncol Rep; 2021 Aug; 23(10):111. PubMed ID: 34342720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replacement of current opioid drugs focusing on MOR-related strategies.
    Busserolles J; Lolignier S; Kerckhove N; Bertin C; Authier N; Eschalier A
    Pharmacol Ther; 2020 Jun; 210():107519. PubMed ID: 32165137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioids and cancer prognosis: A summary of the clinical evidence.
    Ramirez MF; Gorur A; Cata JP
    Neurosci Lett; 2021 Feb; 746():135661. PubMed ID: 33482308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel role of the Mu-opioid receptor in pancreatic cancer: potential link between opioid use and cancer progression.
    Haque MR; Barlass U; Armstrong A; Shaikh M; Bishehsari F
    Mol Cell Biochem; 2022 May; 477(5):1339-1345. PubMed ID: 35138511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Perioperative Opioids on Cancer-Relevant Circulating Parameters: Mu Opioid Receptor and Toll-Like Receptor 4 Activation Potential, and Proteolytic Profile.
    Xie N; Matigian N; Vithanage T; Gregory K; Nassar ZD; Cabot PJ; Shaw PN; Kirkpatrick CMJ; Cao KL; Sturgess D; Parat MO
    Clin Cancer Res; 2018 May; 24(10):2319-2327. PubMed ID: 29511031
    [No Abstract]   [Full Text] [Related]  

  • 6. Opioids and cancer recurrence.
    Juneja R
    Curr Opin Support Palliat Care; 2014 Jun; 8(2):91-101. PubMed ID: 24759319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postsynaptic signaling via the [mu]-opioid receptor: responses of dorsal horn neurons to exogenous opioids and noxious stimulation.
    Trafton JA; Abbadie C; Marek K; Basbaum AI
    J Neurosci; 2000 Dec; 20(23):8578-84. PubMed ID: 11102461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current strategies toward safer mu opioid receptor drugs for pain management.
    Ehrlich AT; Kieffer BL; Darcq E
    Expert Opin Ther Targets; 2019 Apr; 23(4):315-326. PubMed ID: 30802415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. μ-Opioid receptor 6-transmembrane isoform: A potential therapeutic target for new effective opioids.
    Convertino M; Samoshkin A; Gauthier J; Gold MS; Maixner W; Dokholyan NV; Diatchenko L
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Oct; 62():61-7. PubMed ID: 25485963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.
    Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA
    Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bifunctional μ opioid and σ
    Zhuang T; Xiong J; Hao S; Du W; Liu Z; Liu B; Zhang G; Chen Y
    Eur J Med Chem; 2021 Nov; 223():113658. PubMed ID: 34175542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer.
    Lennon FE; Mirzapoiazova T; Mambetsariev B; Poroyko VA; Salgia R; Moss J; Singleton PA
    PLoS One; 2014; 9(3):e91577. PubMed ID: 24662916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer.
    Zylla D; Gourley BL; Vang D; Jackson S; Boatman S; Lindgren B; Kuskowski MA; Le C; Gupta K; Gupta P
    Cancer; 2013 Dec; 119(23):4103-10. PubMed ID: 24104703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the norepinephrine transporter (NET) inhibition on μ-opioid receptor (MOR)-induced anti-nociception in a bone cancer pain model.
    Ono H; Nakamura A; Kanbara T; Minami K; Shinohara S; Sakaguchi G; Kanemasa T
    J Pharmacol Sci; 2014; 125(3):264-73. PubMed ID: 24965165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioids and breast cancer recurrence.
    Cronin-Fenton D
    Curr Opin Support Palliat Care; 2019 Jun; 13(2):88-93. PubMed ID: 30925533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spinal Opioid Tolerance Depends upon Platelet-Derived Growth Factor Receptor-
    Puig S; Barker KE; Szott SR; Kann PT; Morris JS; Gutstein HB
    Mol Pharmacol; 2020 Oct; 98(4):487-496. PubMed ID: 32723769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis.
    Pelechas E; Voulgari PV; Drosos AA
    Expert Opin Pharmacother; 2020 Dec; 21(17):2153-2160. PubMed ID: 33135514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic ethanol consumption in rats produces opioid antinociceptive tolerance through inhibition of mu opioid receptor endocytosis.
    He L; Whistler JL
    PLoS One; 2011; 6(5):e19372. PubMed ID: 21602922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRPV1 and MOR working in tandem: implications for pain and opioids use.
    Abdullah N; Altier C
    Neuropsychopharmacology; 2020 Jan; 45(1):225-226. PubMed ID: 31501526
    [No Abstract]   [Full Text] [Related]  

  • 20. Abuse Potential of Biased Mu Opioid Receptor Agonists.
    Negus SS; Freeman KB
    Trends Pharmacol Sci; 2018 Nov; 39(11):916-919. PubMed ID: 30343727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.